Suzuken and FRONTEO conclude a partnership agreement for the "Conversational Dementia Diagnosis Support AI Program" business

Home » corporate » News » 2022 » Suzuken and FRONTEO conclude a partnership agreement for the "Conversational Dementia Diagnosis Support AI Program" business
2022.02.15 Press release

--To the press -

Suzuken and FRONTEO conclude a partnership agreement for the "Conversational Dementia Diagnosis Support AI Program" business

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 Suzuken Co., Ltd. (Headquarters: Nagoya City, Aichi Prefecture, President: Hiromi Miyata, hereinafter "Suzuken") and FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter "FRONTEO") We have signed a partnership agreement for the "Conversational Dementia Diagnosis Support AI Program" business.

 

 Suzuken and FRONTEO signed a basic agreement in November 2021 to work on the construction of the first distribution and distribution system dedicated to AI medical device programs in Japan, and to collaborate on the conversational dementia diagnosis support AI program business. is.With this alliance agreement, this project has been formally agreed.

 

 The conversational dementia diagnosis support AI program utilizes FRONTEO's unique AI technology to analyze the conversation between the medical staff and the patient for about 5 to 10 minutes to determine the presence or absence of cognitive dysfunction in the patient. is.As the world's first AI medical device for diagnosing dementia using natural language, clinical trials started in April 2021, the target number of registered cases was achieved in December of the same year, and the process for applying for regulatory approval is currently underway. We are.

 

 Suzuken and FRONTEO will contribute to the promotion of DX in medical care while aiming for early market penetration of AI medical devices such as this program, market expansion, and stable supply.

 

 The impact of this matter alone on the business results of both companies for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

 


■ About Suzuken
 URL:https://www.suzuken.co.jp/
The Suzuken Group has defined its business domain as "health creation," not only wholesale of ethical drugs, which is its core business, but also research, development, and manufacturing of new drugs, support for drug manufacturers, insurance pharmacies, and nursing care. We are comprehensively developing businesses related to medical care and health.In addition, it is the only pharmaceutical wholesale business that has a distribution function (“medical distribution platform”) from pharmaceutical manufacturers to wholesalers, and from wholesalers to medical institutions and insurance pharmacies, from the perspectives of manufacturers, medical institutions, insurance pharmacies, and even patients. It has the advantage of being able to respond to diversifying and sophisticated medical distribution needs in a one-stop manner.

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder", and "Looca Cross" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

■ About conversational dementia diagnosis support AI program URL:https://lifescience.fronteo.com/aidevice/dementia/
The "Conversational Dementia Diagnosis Support Program" (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder" to enable cognitive dysfunction from daily conversation between a doctor and a patient for about 5 to 10 minutes. It is a system that can screen. FRONTEO believes that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which has entered a super-aging society. I am. We started clinical trials in April 2021 and are currently working toward early manufacturing and marketing approval and early launch.Patent registration number: Patent No. 4

■ About Concept Encoder URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.

This press release is a joint press release between Suzuken and FRONTEO.Please note that it may be delivered in duplicate from both companies.

 

<Contact information for the press>

 

Suzuken Co., Ltd. Corporate Communication Department Hayashi
461 Higashikatahamachi-cho, Higashi-ku, Nagoya 8701-8
TEL: 052-950-6307 FAX: 052-961-4071

PR Department, FRONTEO, Inc.

Email: pr_contact@fronteo.com